Ontunisertib

Overview

Ontunisertib (AGMB-129) is an orally active and selective gastrointestinal-restricted ALK5 (TGFβR1) inhibitor. Ontunisertib blocks signalling of the pro-fibrotic TGFβ pathway. Ontunisertib can be used for the research of fibrostenotic Crohn’s disease.

Application

Products | Products > Disease Areas > Crohn's Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Digestive System Inflammation | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > TGF-β Receptor

Product Information

• Catalog No.: HY-168990
• CAS No.: 2647949-48-0
• Molecular Formula: C27H21F2N5O
• Molecular Weight: 469.49
• Purity: 99.95%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.32 mM); Clear solution
• Availability: In-stock

Source

Original product source